{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT02148744",
      "orgStudyIdInfo": {
        "id": "XmAb7195-01"
      },
      "organization": {
        "fullName": "Xencor, Inc.",
        "class": "INDUSTRY"
      },
      "briefTitle": "Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis",
      "officialTitle": "A Randomized, Double-Blinded, Placebo-Controlled, Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of XmAb®7195"
    },
    "statusModule": {
      "statusVerifiedDate": "2017-01",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2014-05"
      },
      "primaryCompletionDateStruct": {
        "date": "2015-09-21",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2015-09-21",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2014-05-19",
      "studyFirstSubmitQcDate": "2014-05-22",
      "studyFirstPostDateStruct": {
        "date": "2014-05-28",
        "type": "ESTIMATED"
      },
      "lastUpdateSubmitDate": "2017-01-23",
      "lastUpdatePostDateStruct": {
        "date": "2017-01-24",
        "type": "ESTIMATED"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "Xencor, Inc.",
        "class": "INDUSTRY"
      }
    },
    "oversightModule": {
      "oversightHasDmc": false
    },
    "descriptionModule": {
      "briefSummary": "This first-in-human (FIH) study is a randomized, double-blinded, placebo-controlled, ascending dose study to investigate the safety, tolerability, and pharmacokinetics of XmAb7195 in adult healthy volunteers and in adult subjects with elevated IgE levels."
    },
    "conditionsModule": {
      "conditions": [
        "Allergic Rhinitis",
        "Allergic Conjunctivitis",
        "Atopic Dermatitis"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "SINGLE_GROUP",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "QUADRUPLE",
          "whoMasked": [
            "PARTICIPANT",
            "CARE_PROVIDER",
            "INVESTIGATOR",
            "OUTCOMES_ASSESSOR"
          ]
        }
      },
      "enrollmentInfo": {
        "count": 72,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "XmAb7195 or Placebo",
          "type": "EXPERIMENTAL",
          "interventionNames": [
            "Biological: XmAb7195",
            "Biological: Placebo"
          ]
        }
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "XmAb7195",
          "description": "Part 1 and 2: Single IV infusion of XmAb7195 or placebo Part 3: Two-dose sequential IV infusion of XmAb7195 or placebo on Day 1 and Day 8",
          "armGroupLabels": [
            "XmAb7195 or Placebo"
          ]
        },
        {
          "type": "BIOLOGICAL",
          "name": "Placebo",
          "armGroupLabels": [
            "XmAb7195 or Placebo"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Number of adverse events including type and severity",
          "description": "Number, type and severity of adverse events, vital signs, electrocardiogram (ECGs), laboratory tests, and physical examinations will be reported during the study from randomization up to Day 43",
          "timeFrame": "Date of randomization up to Day 43"
        },
        {
          "measure": "Number of adverse events including type and severity of a priming IV dose followed by an escalating second IV dose",
          "description": "Number, type and severity of adverse events, vital signs, electrocardiogram (ECGs), laboratory tests, and physical examinations will be reported during the study from randomization up to Day 36",
          "timeFrame": "Date of randomization up to Day 36"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Blood concentration of XmAb7195 and blood levels of human anti-human antibodies after single-dose IV administration of XmAb7195",
          "description": "Pharmocokinetic (PK) analysis for levels of XmAb7195 will be determined in subjects blood from time of initial dosing up to Day 43",
          "timeFrame": "Time of dosing up to Day 43"
        },
        {
          "measure": "Blood concentration of XmAb7195 and blood levels of human anti-human antibodies after a priming IV dose followed by an escalating second IV dose of XmAb7195",
          "description": "Presence of human anti-human antibodies will be assessed from time of dosing up to Day 36",
          "timeFrame": "Time of dosing up to Day 36"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Adult males and females 18 to 50 years of age\n* Parts 1 and 3: Healthy subjects with no clinically significant abnormality identified on medical or laboratory evaluation and no history of any clinically significant disorder, condition, or disease that would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion;\n* Part 2: Otherwise healthy male and female subjects with a history of allergic rhinitis and/or allergic conjunctivitis and/or atopic dermatitis with an elevated serum IgE\n* Subjects who are able and willing to give written informed consent;\n* Subjects who have the ability to complete all study assessments;\n* Subjects who are willing to forego other forms of experimental treatment during the study.\n\nExclusion Criteria:\n\n* Subjects who have a clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, connective tissue diseases, or disorders (other than allergic rhinitis and/or conjunctivitis and/or atopic dermatitis in Part 2) that would pose a significant risk to subject safety or significantly interfere with the study evaluation, procedures, or completion\n* Subjects who are positive for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody and/or human immunodeficiency virus (HIV) Type I or Type II tests at Screening;\n* Subjects who do not agree to use medically acceptable methods of contraception (as defined in the protocol);\n* Subject is pregnant or breast feeding, or planning to become pregnant within 3 months of administration of XmAb7195;\n* Subjects who have used any investigational drug in any clinical trial within 8 weeks prior to admission (Day -1), or have used an experimental monoclonal antibody;\n* Subjects with prior exposure to a monoclonal antibody;\n* Subjects with a history of anaphylaxis;\n* Subjects who have received live vaccines ≤ 3 months from Screening;",
      "healthyVolunteers": true,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "maximumAge": "50 Years",
      "stdAges": [
        "ADULT"
      ]
    },
    "contactsLocationsModule": {
      "overallOfficials": [
        {
          "name": "Ronald Goldwater, MD",
          "affiliation": "Parexel Baltimore Early Phase Clinical Unit",
          "role": "PRINCIPAL_INVESTIGATOR"
        }
      ],
      "locations": [
        {
          "facility": "Parexel Baltimore Early Phase Clinical Unit",
          "city": "Baltimore",
          "state": "Maryland",
          "zip": "21225",
          "country": "United States",
          "geoPoint": {
            "lat": 39.29038,
            "lon": -76.61219
          }
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D065631",
          "term": "Rhinitis, Allergic"
        },
        {
          "id": "D003233",
          "term": "Conjunctivitis, Allergic"
        },
        {
          "id": "D003876",
          "term": "Dermatitis, Atopic"
        }
      ],
      "ancestors": [
        {
          "id": "D012220",
          "term": "Rhinitis"
        },
        {
          "id": "D009668",
          "term": "Nose Diseases"
        },
        {
          "id": "D012140",
          "term": "Respiratory Tract Diseases"
        },
        {
          "id": "D012130",
          "term": "Respiratory Hypersensitivity"
        },
        {
          "id": "D010038",
          "term": "Otorhinolaryngologic Diseases"
        },
        {
          "id": "D006969",
          "term": "Hypersensitivity, Immediate"
        },
        {
          "id": "D006967",
          "term": "Hypersensitivity"
        },
        {
          "id": "D007154",
          "term": "Immune System Diseases"
        },
        {
          "id": "D003231",
          "term": "Conjunctivitis"
        },
        {
          "id": "D003229",
          "term": "Conjunctival Diseases"
        },
        {
          "id": "D005128",
          "term": "Eye Diseases"
        },
        {
          "id": "D012873",
          "term": "Skin Diseases, Genetic"
        },
        {
          "id": "D030342",
          "term": "Genetic Diseases, Inborn"
        },
        {
          "id": "D009358",
          "term": "Congenital, Hereditary, and Neonatal Diseases and Abnormalities"
        },
        {
          "id": "D003872",
          "term": "Dermatitis"
        },
        {
          "id": "D012871",
          "term": "Skin Diseases"
        },
        {
          "id": "D017437",
          "term": "Skin and Connective Tissue Diseases"
        },
        {
          "id": "D017443",
          "term": "Skin Diseases, Eczematous"
        }
      ]
    }
  },
  "hasResults": false
}